Sage Represents Mateon Therapeutics - Leadership in Novel Vascular Targeted TherapySage is representing Mateon Therapeutics, a US-based biopharma company focusing on Vascular Disrupting Agents (VDAs) for orphan oncology...
Opportunity to License or Acquire ES-3000, An Orphan Drug for CML and AMLEscend Therapeutics (www.escendpharma.com) is based in San Diego, CA, and develops small molecule therapeutics for oncology orphan drug...
Sage Group Advises APR on InLicensing and Acquisition of Novel Pharma ProductsABOUT APR Applied Pharma Research s.a. (www.apr.ch; “APR” or the “Company”) is a profitable, well-financed, privately held, Swiss...
Sage Advises Solasia on a Global Partnership for Darinaparsin, a Novel Treatment for Peripheral T CeSolasia has engaged The Sage Group to manage a program to establish a global partnership regarding licensing of its Darinaparsin product...
Sage Represents Luzitin in Licensing of its Redaporfin Combination Therapy for Solid TumoursSage represents Luzitin (www.luzitin.pt) to develop a strategic alliance for its Redaporfin PDT combination therapy for solid tumours....
Isofol Appoints The Sage Group to Identify Strategic Partnerships for its Novel Modufolin® Chemother Isofol (www.isofolmedical.com), a clinical stage pharmaceutical company based in Gothenburg, Sweden, announces that following an...
CNSystems Appoints the Sage Group to Identify Strategic Partnerships for its Non Invasive HemodynamiGraz, Austria, Cambridge UK, and Clinton NJ – January 2015 – CNSystems announces that following an internal strategic assessment, it has...